Patent ID: 11939306
Assignee: CURIS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A method of therapeutically treating cancer in a subject in need thereof comprising administering to the subject an anhydrous crystalline compound having the structure of formula (I),, , and, wherein the cancer is selected from breast cancer, triple-negative breast cancer, glioblastoma, brain stem glioma, osteosarcoma, bone cancer, primary ductal carcinoma, prostate cancer, colon cancer, cancer of the small intestine, rectal cancer, cancer of the anal region, melanoma, epithelial cancer, skin cancer, renal cancer, kidney cancer, cancer of the head or neck, head and neck squamous cell carcinoma (HNSCC), uterine cancer, ovarian cancer, ovarian carcinoma, colorectal cancer, cancer of the peritoneum, stomach cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, cancer of the esophagus, leukemia, chronic leukemia, acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloblastic leukemia, B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma, small lymphocytic non-Hodgkin's lymphoma, myeloma, multiple myeloma, cancer of the bladder, bladder carcinoma, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), gastric carcinoma, prostate adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, colorectal adenocarcinoma, carcinoma of the renal pelvis, hepatocellular cancer, hepatic carcinoma, liver cancer, mesothelioma, Waldenstrom's macroglobulinemia, nodular sclerosis Hodgkin's lymphoma (NSHL), follicular non-Hodgkin's lymphoma, small lymphocytic non-Hodgkin's lymphoma, T cell lymphoma, cutaneous T-cell lymphoma, small lymphocytic lymphoma, lymphocytic lymphoma, primary CNS lymphoma, pancreatic cancer, and pancreatic adenocarcinoma.